(Q37950921)

25 August 2017

title

The use of combination therapy in the treatment of postmenopausal osteoporosis (English)

1 reference

25 August 2017

0 references

Juliet Compston

1

1 reference

25 August 2017

publication date

29 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

41

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

11-18

1 reference

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Could strontium ranelate have a synergistic role in the treatment of osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-011-9554-2

The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years

21 January 2018

1 reference

12 December 2020

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

12 December 2020

A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women

1 reference

12 December 2020

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis

1 reference

12 December 2020

The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate—is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group

1 reference

12 December 2020

Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial

1 reference

12 December 2020

Combination therapy for postmenopausal osteoporosis

1 reference

12 December 2020

Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

12 December 2020

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment

1 reference

12 December 2020

10.1007/S12020-011-9554-2

Identifiers

DOI

1 reference

25 August 2017

1 reference